-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gilead Sciences announced a meeting with Jounce Therapeutics (JNCE. US) has reached a partnership agreement under which Gilead will obtain exclusive research and development licenses for Jounce's JTX-1811 project, pay Jounce an $85 million advance and make a $35 million equity investment.
, Jounce is expected to receive follow-up payments of up to $685 million in the future based on clinical, regulatory and commercial milestones.
it is understood that Jounce was founded in 2013 and co-founded by James P. Allison, professor of immunology and dean of the department at the Anderson Cancer Center at the University of Texas, usa, who jointly won the 2018 Nobel Prize in Physiology or Medicine on October 1, 2018.
Jounce's commitment to immunotherapy is characterized not by direct treatment of patient tumors, but by managing the patient's immune system to enable it to independently detect and attack cancer cells and malignancies.
2013, Jounce received $47 million in round A financing and $56 million in round B financing in 2015.
the key projects currently being developed by Jounce include monoclonal antibody JTX-2011, which stimulates induced costulent molecules, and super-T cells that disrupt target interactions on tumor-related macrophages.
JTX-1811 in this protocol is a monoclonal antibody designed to selectively remove immunosuppressive tumor-immersive regulatory T (TITR) cells.
target of JTX-1811 is CCR8, a chemical factor subject that is rich in TITR cells.
when JTX-1811 binds to CCR8, it can target the removal of TITR cells through enhanced antibody-dependent cytotoxic mechanisms.
antibody will submit an IND application in the first half of 2021.
Jounce will be responsible for the early development of the JTX-1811 until IND approval is obtained, after which Gilead will have an exclusive interest in the development of the JTX-1811.
. William A. Lee, Executive Vice President of Scientific Research and Development at Gilead, said JTX-1811 is a complement to Gilead's other cancer candidates and has the potential to be a new therapy for 'first-in-class' for patients with solid and hematopathic tumors.
source: Medical Valley !-- content display ends -- !-- determine whether the login ends.
